ANI Pharmaceuticals traded at $77.77 this Friday February 20th, decreasing $0.33 or 0.42 percent since the previous trading session. Looking back, over the last four weeks, ANI Pharmaceuticals lost 9.06 percent. Over the last 12 months, its price rose by 34.23 percent. Looking ahead, we forecast ANI Pharmaceuticals to be priced at 75.36 by the end of this quarter and at 68.57 in one year, according to Trading Economics global macro models projections and analysts expectations.
ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, oncology products (anti-cancer), hormones and steroids, and complex formulations. Its products include Aminocaproic Acid Tablets USP, ApexiCon E (diflorasone diacetate cream USP (emollient)), Arimidex (anastrozole) tablets, Atacand HCT (candesartan cilexetil - hydrochlorothiazide) Tablets, Atacand (candesartan cilexetil) Tablets, Bexarotene Capsules, Bicalutamide Tablets USP, and more. Its branded products include Cortenema, Cortrophin gel, Cortrophin-Zinc, Inderal LA, Inderal XL, InnoPran XL, Lithobid, Reglan, and Vancocin. It operates across three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota and one is located in Oakville, Ontario.